Navigation Links
Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
Date:9/13/2007

ecutive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding CEO and advisor, international business development. Sucampo Pharmaceuticals' first product, AMITIZA(R), received marketing approval from the U.S. Food and Drug Administration in January 2006 for the treatment of Chronic Idiopathic Constipation in adults. AMITIZA is co-promoted in the United States and Canada through an alliance between Sucampo Pharmaceuticals and Takeda Pharmaceutical Company Limited (Osaka, Japan). Sucampo Pharmaceuticals' sales force targets the institutional marketplace, including academic medical centers and long- term care facilities, while Takeda focuses on office-based specialty and primary care physicians. To learn more about Sucampo Pharmaceuticals and its products, visit http://www.sucampo.com.

Takeda Pharmaceuticals North America, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, Takeda currently markets products for diabetes, insomnia, wakefulness and gastroenterology. The company has a robust pipeline with compounds in development for diabetes, cardiovascular disease and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit http://www.tpna.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Sucampo Pharmaceuticals, Inc. are forward-looking statements made under the provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words "project," "believe," "anticipate," "plan,"
'/>"/>

SOURCE Sucampo Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... HILL, N.C. , Nov. 21, 2014 /PRNewswire/ ... healthcare system. Undoubtedly, the growing influence of patients ... spend for marketing interactions. Now, more than ever, ... retain patients for medical products is essential. ... firm, Best Practices, LLC, benchmarked companies spent about ...
(Date:11/21/2014)... SAN CLEMENTE, Calif. , Nov. 21, 2014 /PRNewswire/ ... Lab Coats and Performance Scrubs carried out a new ... the medical industry,s very first "limited edition" lab ... the first female professors of surgery in the world. ... departure from its unisex predecessors, with a sleek envelope ...
(Date:11/21/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... Award for Vision, Innovation, and Leadership has been awarded to ... award recognizes an individual who has had a significant impact ... for several decades. "I am honored to ... Peltz , Ph.D., CEO of PTC Therapeutics, Inc. "When I ...
Breaking Medicine Technology:New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3
(Date:11/22/2014)... FRIDAY, Nov. 21, 2014 (HealthDay News) -- Many young ... smoke, but a new study finds fumes from the ... been linked to an increased risk for leukemia in ... 21 in the journal Cancer Epidemiology, Biomarkers & ... hookah tobacco smoking is not a safe alternative to ...
(Date:11/22/2014)... Steven Reinberg HealthDay Reporter ... better when patients are treated in an ambulance by a ... researchers report. The sooner patients get the clot dissolver ... after a stroke, the researchers noted. For the best outcome, ... after stroke symptoms start, the researchers said. "The so-called ...
(Date:11/22/2014)... HealthDay Reporter FRIDAY, Nov. 21, ... homes may commonly deal with aggressive or inappropriate behavior from ... 10 centers in New York state found that, in the ... were involved in some type of incident with a fellow ... someone yelling or cursing at another resident. In other cases, ...
(Date:11/21/2014)... Los Angeles, CA (PRWEB) November 21, 2014 ... is now creating picture-perfect smiles for patients in preparation ... are bonded to the fronts of teeth, look completely ... flaws. In certain situations, veneers are also valued for ... for most patients and can be used on one ...
(Date:11/21/2014)... 2014 (HealthDay News) -- Seeking to make it tougher ... and Drug Administration on Thursday approved a new hydrocodone ... -- best known by the brand name Vicodin -- ... to a surge in dangerous addictions across the United ... ER (hydrocodone bitartrate) is an extended-release tablet to treat ...
Breaking Medicine News(10 mins):Health News:Hookahs Deliver Toxic Benzene in Every Puff, Study Shows 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 3Health News:Los Angeles Porcelain Veneers Dentist, Dr. Kevin Sands, Now Creates Picture-Perfect Smiles for Patients for the Holiday Season 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 3
... A study has indicated that inflammatory bowel disease in women ... two times.// , ,Diseases such as Crohn's disease and ... weight babies or premature babies. Yet, the 'silver lining' exists ... has certainly reduced the risks. ,The St. ...
... by a US research company has highlighted the overriding ... health// problem facing society and their children today. , ... adults, found that nearly 27% named 'obesity', as the ... followed next with 16% strongly advocating action, while ...
... that could be used as a bioterrorist tool eludes ... better understood, University of Iowa// researchers report in the ... ,This bacterium, Francisella tularensis, is found naturally in ... insect bites, contact with infected rabbits or ingesting contaminated ...
... Food Technology Plant Special Research Centre (CeRPTA) is a ... called as gluten sensitive enteropathy. This product was successfully ... enhanced nutritive value and increased shelf life. ... sufferers to follow a strictly gluten-free diet for their ...
... of Texas M. D. Anderson Cancer Center suggest that the ... 40 years reduced the tumor growth in the// human pancreas ... ,The Journal of the National Cancer Institute issued on Dec.20 ... is three times more effective than just the administration of ...
... resonance imaging technique developed at the University of ... of neurological problems, such as// Chiari malformations, hydrocephalus ... use through a $1.4 million National Institutes of ... project, which draws on bioengineering, radiology and neurosurgery, ...
Cached Medicine News:Health News:Clues Found On How Deadly Bacterium Gains Foothold 2Health News:Clues Found On How Deadly Bacterium Gains Foothold 3Health News:Gluten Free Bread: Boon for Celiac Disease 2Health News:Anti Allergy Drugs Reduce Tumor Growth 2Health News:Anti Allergy Drugs Reduce Tumor Growth 3Health News:New MRI Technique Measures Intracranial Pressure in Brain Disorder 2
For the quantitative in vitro determination of Lipase in human serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
For the quantitative in vitro determination of Ammonia in plasma...
For the quantitative in vitro determination of Potassium in serum or plasma....
Medicine Products: